Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Interferon beta-1b
Drug ID BADD_D01170
Description Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Indications and Usage Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.
Marketing Status approved
ATC Code L03AB08
DrugBank ID DB00068
KEGG ID D00746
MeSH ID D000068576
PubChem ID Not Available
TTD Drug ID D0CQ2O
NDC Product Code 0078-0569; 50419-524
UNII TTD90R31WZ
Synonyms Interferon beta-1b | Beta-IFN-1b | Ser(17) IFN-beta | Interferon Beta, Serine(17) | Serine(17) Interferon Beta | Interferon beta 1b | IFN-Beta Ser | Interferon Beta, Ser(17) | Betaseron | Beta-Seron | Beta Seron | Extavia | Betaferon
Chemical Information
Molecular Formula Not Available
CAS Registry Number 145155-23-3
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Seizure17.12.03.001--
Skin discolouration23.03.03.005--Not Available
Skin disorder23.03.03.007--Not Available
Suicidal ideation19.12.01.003--
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thyroid disorder05.02.01.002--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
White blood cell count decreased13.01.06.012--
Urosepsis20.08.02.002; 11.01.11.005--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Affect lability19.04.01.001--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Psychotic disorder19.03.01.002--
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Heavy menstrual bleeding21.01.03.005--Not Available
Intermenstrual bleeding21.01.01.015--Not Available
The 3th Page    First    Pre   3    Total 3 Pages